Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Lung Cancer

• Publication date

  2001-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0169-5002(01)00210-0PMID 11551413
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer

  2004cited by this paper
• Comparison of features of human breast cancer cell lines and their corresponding tumors.

  1999cited by this paper
• Comparison of features of human lung cancer cell lines and their corresponding tumors.

  1999cited by this paper
• NY-ESO-1 may be a potential target for lung cancer immunotherapy.

  1999cited by this paper
• Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with resectable non-small-cell lung cancer.

  1999cited by this paper
• PGP9.5 as a candidate tumor marker for non-small-cell lung cancer.

  1999cited by this paper
• Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth

  1999cited by this paper
• Cancer statistics, 1998

  1998cited by this paper
• CD80 expression in an HLA‐A2‐positive human non‐small cell lung cancer cell line enhances tumor‐specific cytotoxicity of HLA‐A2‐positive T cells derived from a normal donor and a patient with non‐small cell lung cancer

  1998cited by this paper
• Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

  1998cited by this paper
• Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung.

  1998cited by this paper
• Occult lung cancer beyond bronchoscopic visibility in sputum-cytology positive patients.

  1998cited by this paper
• Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer.

  1998cited by this paper
• HLA class I and class II expression of pulmonary adenocarcinoma cells and the influence of interferon gamma.

  1998cited by this paper
• Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells.

  1997cited by this paper
• Interferon-γ Enhances Susceptibility of Cervical Cancer Cells to Lysis by Tumor-Specific Cytotoxic T Cells

  1997cited by this paper
• Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells.

  1997cited by this paper
• Expression of costimulatory molecules B7‐1 (CD80) and B7‐2 (CD86) on human hepatocellular carcinoma

  1997cited by this paper
• Induction of Autologous Tumor‐Specific Cytotoxic T‐Lymphocyte Activity Against a Human Renal Carcinoma Cell Line by B7–1 (CD80) Costimulation

  1996cited by this paper
• Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

  1996cited by this paper
• Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

  1996cited by this paper
• Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.

  1996cited by this paper
• Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells.

  1996cited by this paper
• Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

  1996cited by this paper
• A randomized trial of adoptive immunotherapy with tumor‐infiltrating lymphocytes and interleukin‐2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer

  1996cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon γ and interleukin-10

  1996cited by this paper
• B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines.

  1996cited by this paper
• NCI‐navy medical oncology branch cell line data base

  1996cited by this paper
• Errata

  1996cited by this paper
• Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.

  1995cited by this paper
• Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study.

  1995cited by this paper
• Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer.

  1995cited by this paper
• Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.

  1995cited by this paper
• Expression of the co‐stimulatory molecule B7 on melanoma cells

  1994cited by this paper
• Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

  1994cited by this paper
• Expression of mage genes by non‐small‐cell lung carcinomas

  1994cited by this paper
• Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy.

  1994cited by this paper
• HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.

  1994cited by this paper
• Costimulation of T cells for tumor immunity.

  1993cited by this paper
• Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

  1993cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper
• Ganglioside antigens expressed by human cancer cells.

  1991cited by this paper
• Interleukin-2 with ex vivo activated killer cells: therapy of advanced non-small-cell lung cancer.

  1991cited by this paper
• Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung.

  1990cited by this paper
• [CEA in lung cancer: CEA immunohistochemical study of 150 cases].

  1990cited by this paper
• [CEA in lung cancer: CEA immunohistochemical study of 150 cases].

  1990cited by this paper
• Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer.

  1989cited by this paper
• Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

  1987cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Correspondence re: Martin Brower et al. Growth of Cell Lines and Clinical Specimens of Human Non-Small Cell Lung Cancer in a Serum-free Defined Medium. Cancer Res., 46: 798–806, 1986

  1986cited by this paper
• Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis.

  1986cited by this paper
• Re: Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

  1986cited by this paper
• Cell culture methods for human lung cancer.

  1986cited by this paper
• Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.

  1986cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• [Cancer of the lung].

  1952cited by this paper

• Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations

  2025cites this paper
• Ultrasensitive multiplex detection of lung cancer EV-associated immune checkpoints using a mesoporous gold enhanced SERS biosensor.

  2025cites this paper
• A mesoporous gold biosensor to investigate immune checkpoint protein heterogeneity in single lung cancer cells.

  2024cites this paper
• Interferon Induced Upregulation of Tripartite Motif 34 (TRIM34) Leads Apoptotic Cell Death in Lung Adenocarcinoma

  2024cites this paper
• Prospects of anti-GD2 immunotherapy for retinoblastoma

  2024cites this paper
• Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

  2024cites this paper
• Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies

  2023cites this paper
• Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

  2022cites this paper
• Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer

  2022cites this paper
• Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer

  2022cites this paper
• Rapidly Growing Mycobacterium Species: The Long and Winding Road from Tuberculosis Vaccines to Potent Stress-Resilience Agents

  2021cites this paper
• CAR-T cell therapy for lung cancer: a promising but challenging future

  2020cites this paper
• Role of the tumor microenvironment on the progression of lung cancer, The

  2019cites this paper
• A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma

  2018cites this paper
• 19F-MRI to Monitor Therapeutic Cell Migration and Distribution

  2018cites this paper
• Chemical and genetic control of IFNγ‐induced MHCII expression

  2018cites this paper
• A tail-based test for differential expression analysis and pathway analysis in RNA-sequencing data

  2017cites this paper
• Chemical and genetic control of IFNγ-induced MHCII expression

  2017cites this paper
• Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy.

  2016cites this paper
• PIWIL2 promotes progression of non-small cell lung cancer by inducing CDK2 and Cyclin A expression

  2015cites this paper
• Effective capture of circulating tumor cells from a transgenic mouse lung cancer model using dendrimer surfaces immobilized with anti-EGFR.

  2015cites this paper
• B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer

  2014cites this paper
• Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10

  2014cites this paper
• immunotherapy strategy tumors in vivo enhances antitumor immunity induced by an active Augmenting major histocompatibility complex class I expression by murine

  2013cites this paper
• Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cell–based Vaccine for Refractory Lung Adenocarcinoma

  2013cites this paper
• Immunotherapy in Lung Cancer: “B7-Bombers” and Other New Developments

  2013cites this paper
• Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity.

  2012cites this paper
• Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials.

  2012cites this paper
• Theinfluenceofthe"bio-coat's"type ofculturedishesontheprimarycultures oflungcancercells

  2011cites this paper
• The influence of the “ bio-coat ’ s ” type of culture dishes on the primary cultures of lung cancer cells

  2011cites this paper
• Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy

  2011cites this paper
• The immunoregulatory mechanisms of carcinoma for its survival and development

  2011cites this paper
• Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer

  2011cites this paper
• Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

  2011cites this paper
• Establishment of shared antigen reactive cytotoxic T lymphocyte using co-stimulatory molecule introduced autologous cancer cells.

  2010cites this paper
• Generation and Characterization of Non-Small-Cell Lung Cancer Cell Lines and Clones for Use in the Study of Immunotherapy

  2010cites this paper
• THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY

  2009cites this paper
• HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody

  2009cites this paper
• Paradoxical concentration effect of a homodimerizing antibody against a human non-small cell lung cancer cell line

  2009cites this paper
• Cellular immunotherapy (CI), where have we been and where are we going?

  2009cites this paper
• Unmet need in lung cancer: can vaccines bridge the gap?

  2008cites this paper
• Identification of HLA-CW3, GNAS and IMPA as Cytotoxic T-Lymphocyte (CTL) Target Antigens Using an Allogeneic Mixed Lymphocyte Tumor Cell Culture (MLTC) System and Subsequent cDNA Library Screening

  2007cites this paper
• Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells.

  2007cites this paper
• Present and future of lung cancer vaccines

  2006cites this paper
• Vaccines for lung cancer.

  2006cites this paper
• B7-H3 and B7-H4 expression in non-small-cell lung cancer.

  2006cites this paper
• Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors

  2006cites this paper
• The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC).

  2005cites this paper
• Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

  2005cites this paper
• Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines

  2005cites this paper
• Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.

  2004influential citation
• Vaccines for Lung Cancer

  2004cites this paper
• On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.

  2004cites this paper
• Lung cancer detection by a RT-nested PCR using MAGE A1--6 common primers.

  2004cites this paper
• Accessory cell function of airway epithelial cells.

  2004cites this paper
• Autologous dendritic cell vaccines for non-small-cell lung cancer.

  2004cites this paper
• Recent advances in the cellular immunotherapy of human cancer

  2003cites this paper
• Growth and Functional Reactivity of Lymphocytes Obtained from Three Anatomic Compartments in Patients with Non–Small-Cell Lung Cancer (NSCLC)

  2003cites this paper
• Generation of Renal Cell Carcinoma-specific CD4 + /CD8 + T Cells Restricted by an HLA-39 from a RCC Patient Vaccinated with GM-CSF Gene-Transduced Tumor Cells

  2003cites this paper